The Ferumoxytol for Anemia of CKD Trial (FACT)—a randomized controlled trial of repeated doses of ferumoxytol or iron sucrose in patients on hemodialysis: background and rationale

Autor: Iain C. Macdougall, Naomi V. Dahl, Kristine Bernard, Zhu Li, Alka Batycky, William E. Strauss
Jazyk: angličtina
Rok vydání: 2017
Předmět:
Zdroj: BMC Nephrology, Vol 18, Iss 1, Pp 1-10 (2017)
Druh dokumentu: article
ISSN: 1471-2369
DOI: 10.1186/s12882-017-0523-8
Popis: Abstract Background Iron deficiency anemia (IDA) is a common manifestation of chronic kidney disease (CKD), affecting most patients on hemodialysis and imposing a substantial clinical burden. Treatment with iron supplementation increases hemoglobin levels and can reduce the severity of anemia in patients with CKD. While correcting anemia in these patients is an important therapeutic goal, there is a lack of long-term trials directly comparing intravenous iron therapies in patients with CKD receiving hemodialysis. Methods/Design The Ferumoxytol for Anemia of CKD Trial (FACT) is a 13-month, open-label, randomized, multicenter, international, prospective study with 2 substudies. Entry criteria for the main study include adults with IDA (defined as hemoglobin
Databáze: Directory of Open Access Journals
Externí odkaz: